Royal Philips has introduced the next-generation Bridge Plus Occlusion Balloon, designed to help electrophysiology teams rapidly control bleeding during rare but life-threatening superior vena cava (SVC) tears. These complications can occur during transvenous lead extraction (TLE) procedures, where quick intervention is critical to patient survival.
Addressing a Rare but Critical Risk
TLE procedures are commonly performed to remove leads from cardiac implantable electronic devices such as pacemakers and defibrillators. Although generally safe, SVC tears occur in fewer than 0.5% of cases but can quickly become fatal without immediate action. Therefore, preparedness and rapid response remain essential in these scenarios.
Rapid Deployment for Life-Saving Intervention
Building on technology used in over 50,000 procedures, the Bridge Plus balloon enables clinicians to respond within minutes. The device can deploy in under two minutes, reduce up to 90% of blood loss, and maintain hemostasis for at least 30 minutes. Consequently, it provides physicians with valuable time to stabilize patients and transition to surgical repair.
Clinical Evidence Supports Improved Outcomes
Importantly, studies show that survival rates in SVC tear cases improved significantly—from 56.9% to 88.2%—when an occlusion balloon was pre-positioned and readily available. According to Thomas Callahan, having such a device staged in advance can dramatically enhance response time and improve patient outcomes during emergencies.
Advanced Design Enhances Precision and Flexibility
As per the Philips Press release, the Bridge Plus balloon features a low-pressure, compliant design with radiopaque markers for precise placement. Additionally, it adapts to a wide range of patient anatomies and allows deployment even if fluoroscopy becomes unavailable. This flexibility further strengthens procedural safety.
Expanding Access and Clinical Adoption
Currently, the device is commercially available in the United States, with international rollout expected later in 2026, pending regulatory approvals. Furthermore, Philips will showcase the technology at the Heart Rhythm Society 2026 in Chicago, highlighting its commitment to advancing safer cardiac procedures.